Table 1.

The association of variant rs7210100 at 17q21 with prostate cancer risk in men of African ancestry.

Stage 1 Studies	Cases/Controlsa	RAF in controls	OR(95% CI)b	P-valuec
MEC	1060/1055	0.04	1.58(1.21–2.08)	8.8×10−4
SCCS	201/412	0.05	1.40(0.85–2.31)	0.19
PLCO	227/239	0.05	1.44(0.82–2.52)	0.21
CPS-II	64/112	0.07	0.66(0.24–1.78)	0.41
MDA	527/437	0.05	1.39(0.95–2.02)	0.089
IPCG	354/157	0.05	1.54(0.84–2.82)	0.17
LAAPC	288/287	0.06	0.94(0.57–1.56)	0.81
CaP Genes	71/85	0.06	1.72(0.78–3.82)	0.18
DCPD	263/341	0.07	1.14(0.75–1.75)	0.54
KCPCS	141/75	0.05	0.95(0.42–2.16)	0.90
GECAP	224/89	0.05	2.47(1.14–5.34)	0.022
Combined	3,420/3,289		1.40(1.21–1.62)	5.2×10−6
				PHet=0.89d
Stage 2 Studies
SFPCS	86/36	0.04	1.86(0.53–6.55)	0.34
FMHS	125/339	0.06	1.70(0.98–2.93)	0.058
MEC-LAC	551/555	0.04	1.92(1.30–2.83)	9.7×10−4
NCPCS	214/249	0.06	0.92(0.51–1.66)	0.79
WFPCS	58/65	0.04	1.90(0.56–6.42)	0.30
WUPCS	73/153	0.04	1.96(0.76–5.03)	0.16
GHS	264/964	0.07	1.37(0.94–2.01)	0.11
Combined	1,371/2,361		1.55(1.26–1.89)	2.5×10−5
				PHet=0.25d
Stage 3 Studies
SCORE	146/267	0.05	1.58(0.88–2.83)	0.13
PROGRÈS	79/395	0.05	2.64(1.36–5.10)	4.0×10−3
PCBP	246/242	0.05	2.02(1.20–3.39)	7.9×10−3
Combined	471/904		2.07(1.49–2.88)	1.5×10−5
				PHet=0.51d
Stages 1+2+3	5,262/6,554		1.51(1.35–1.69)	3.4×10−13
				PHet=0.58d

^aNumber of cases and controls with genotype data for rs7210100.

^bAdjusted for age and eigenvectors 1–10 in stage 1 (and study in pooled analysis). Adjusted for age in stage 2 and stage 3. Adjusted for age and study in stage 1+2+3 analysis.

^cP for trend (1-d.f.).

^dTest of heterogeneity. RAF: risk allele frequency.